Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1
By J. Lecouter, D. Moritz, Bing Li, G. Phillips, X. H. Liang, H. Gerber, Kenneth J. Hillan, N. Ferrara. Science, 2003
688 citations recorded by the source corpus.
Subfields: Cancer Research, Hepatology, Surgery
View Paper: https://www.semanticscholar.org/paper/f434d6977f922bcf67c552dc795577c782e24fa5
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Hepatology
- J. Llovet
- Jordi Bruix1 , 2
- V. Mazzaferro
- Yujin Hoshida
- T. Greten
- S. Friedman
- A. Villanueva
- G. Michalopoulos
In Surgery
Citations in the corpus
- Focal Gains of Vascular Endothelial Growth Factor A and Molecular Classification of Hepatocellular Carcinoma (2008, background): “Conversely, VEGFA-activated endothelial cells can also produce hepatocyte growth factor in response to increased VEGFA levels, and this elevation stimulates hepatocyte proliferation (49).”
- The biology of VEGF and its receptors (2003, background): “VEGFR-1 activation resulted in the paracrine release of HGF, IL-6 and other hepatotrophic molecules by LSECs, such that hepatocytes were stimulated to proliferate when cultured with LSEC”
- Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. (2018, background): “, hepatocyte growth factor (HGF), in the liver endothelial cells] [46, 47], interaction with PlGF [4, 17, 27], and activation of proteolytic enzymes (e.”
- Liver regeneration (2007, background): “RNAL OF CELLULAR PHYSIOLOGY DOI 10.1002/JCP HGF in liver is produced predominantly by the stellate cells (Schirmacher et al., 1993), but also by hepatic endothelial cells (LeCouter et al., 2003).”
- Preparing the "soil": the premetastatic niche. (2006, background): “In liver sinusoidal endothelial cells, the activation of VEGFR1 results in the paracrine release of hepatocyte growth factor, interleukin-6, and other hepatotrophic molecules that stimulate the proliferation of hepatocytes ( 44 ).”
- Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer (2004, background): “; and in the paracrine release of growth factors from endothelial cell”